
Opinion|Videos|July 13, 2024
ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma
Dr Lipson provides insights surrounding combination therapies in melanoma management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the value of long-term follow-up data in melanoma? How does this impact use of treatment regimens?
- How do you foresee the role of combination therapies evolving in the treatment of melanoma over the next few years?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
3
Pembrolizumab Plus Chemo Boosts PFS, OS in Platinum-Resistant Recurrent Ovarian Cancer: Nicoletta Colombo, MD, PhD
4
Long-Term Data for PHAROS Show Half of Treatment-Naïve Patients Receiving Encorafenib Plus Binimetinib Alive at 4 Years
5